Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program-Reference-Cited by-同舟云学术

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

Published:2019-03-12 Issue:6 Volume:62 Page:926-938
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Matthews David R.,Li Qiang,Perkovic Vlado,Mahaffey Kenneth W.,de Zeeuw Dick,Fulcher Greg,Desai Mehul,Hiatt William R.,Nehler Mark,Fabbrini Elisa,Kavalam Mary,Lee Mary,Neal Bruce

Funder

Janssen Research & Development, LLC

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00125-019-4839-8.pdf

Reference20 articles.

1. Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941–950. https://doi.org/10.1016/S0140-6736(13)60683-2

2. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657. https://doi.org/10.1056/NEJMoa1611925

3. Neal B, Perkovic V, de Zeeuw D et al (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J 166(2):217–223 e211. https://doi.org/10.1016/j.ahj.2013.05.007

4. Neal B, Perkovic V, Matthews DR et al (2017) Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19(3):387–393. https://doi.org/10.1111/dom.12829

5. Neal B, Perkovic V, Mahaffey KW et al (2017) Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19(7):926–935. https://doi.org/10.1111/dom.12924

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medical Optimization of Patients with Symptomatic Peripheral Arterial Disease;Annals of Vascular Surgery;2024-10

2. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

3. Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now;Drugs;2024-09-11

4. Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review;Cardiovascular Diabetology;2024-06-26

5. Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium‐glucose cotransporter‐2 inhibitors versus other medications: A systematic review and meta‐analysis of observational cohort studies;Diabetes, Obesity and Metabolism;2024-04